5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Yidu Tech's 5-Year ROIIC % for the quarter that ended in Mar. 2023 was -71.16%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Yidu Tech's 5-Year ROIIC % or its related term are showing as below:
HKSE:02158's 5-Year ROIIC % is ranked worse than 91.26% of 572
companies
in the Healthcare Providers & Services industry
Industry Median: 1.505
vs HKSE:02158: -71.16
Yidu Tech 5-Year ROIIC % Historical Data
The historical data trend for Yidu Tech's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Yidu Tech's 5-Year ROIIC %
For the Health Information Services subindustry, Yidu Tech's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yidu Tech's 5-Year ROIIC % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yidu Tech's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Yidu Tech's 5-Year ROIIC % falls into.
Yidu Tech 5-Year ROIIC % Calculation
Yidu Tech's 5-Year ROIIC % for the quarter that ended in Mar. 2023 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Yidu Tech (HKSE:02158) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Yidu Tech 5-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Yidu Tech's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Yidu Tech offers healthcare Big Data. It is an AI cloud-based firm providing solutions and tools to aid in more informed decisions to drive better efficiency in clients' strategies. Its clients are hospitals, pharmaceutical, biotech and medical device firms, research institutions, insurance companies, patients, and regulators. It three business segments are: Big Data platform and solutions, which partners with hospitals and policymakers to drive better efficiency; life sciences solutions, which enables better probability of clinical trial success with less drug development time and cost; and health management solutions, which helps with patient management. The Big Data platform accounted for 33% of revenue, life science solutions 30%, and health management solutions 27%, in fiscal 2022.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02158 has been successfully added to your 